37901-92-1

Basic information

• Product Name: 4-(acetylamino)-3-methylbenzoic acid
• Synonyms: 4-(acetylamino)-3-methylbenzoic acid;AKOS BBV-013836;UKRORGSYN-BB BBV-013836;4-(acetylamino)-3-methylbenzoic acid(SALTDATA: FREE);4-Acetamido-3-methylbenzoic acid
• CAS NO: 37901-92-1
• Molecular Formula: C₁₀H₁₁NO₃
• Molecular Weight: 193.1992
• Mol File: 37901-92-1.mol

Chemical Properties

• Melting Point: 114-116 °C
• Boiling Point: 411°Cat760mmHg
• Flash Point: 202.4°C
• Appearance: /
• Density: 1.276g/cm³
• Vapor Pressure: 1.72E-07mmHg at 25°C
• Refractive Index: 1.607
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.34±0.10(Predicted)
• CAS DataBase Reference: 4-(acetylamino)-3-methylbenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(acetylamino)-3-methylbenzoic acid(37901-92-1)
• EPA Substance Registry System: 4-(acetylamino)-3-methylbenzoic acid(37901-92-1)

Safety Data

• Hazardous Substances Data: 37901-92-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(acetylamino)-3-methylbenzoic acid is used as an intermediate in the synthesis of various drugs and pharmaceuticals for its potential anti-inflammatory and analgesic properties. It serves as an important building block in the development of medications aimed at treating pain and inflammation-related conditions.

InChI:InChI=1/C10H11NO3/c1-6-5-8(10(13)14)3-4-9(6)11-7(2)12/h3-5H,1-2H3,(H,11,12)(H,13,14)

Upstream product

• 2486-70-6 4-amino 3-methylbenzoic acid 
• 108-24-7 acetic anhydride 
• 64-19-7 acetic acid 
• 2050-43-3 N-(2,4-dimethylphenyl)acetamide 

Downstream Products

• 808745-06-4 ethyl 4-acetamido-3-methyl-5-nitrobenzoate 
• 856839-94-6 ethyl 3,4-diamino-5-methylbenzoate 
• 808745-05-3 ethyl 4-acetamido-3-methylbenzoate 
• 668276-43-5 methyl 3,4-diamino-5-methylbenzoate 
• 668276-44-6 methyl 4-amino-3-methyl-5-nitrobenzoate 
• 1263818-07-0 methyl 4-acetamido-3-methyl-5-nitrobenzoate 
• 37901-93-2 4-acetamido-3-methyl-5-nitrobenzoic acid 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR

Disclosed are heterocyclic compounds as inhibitors of FGFR-4 represented by formula (I). Also disclosed is a pharmaceutical composition that includes an inhibitor of FGFR-4. The compounds maybe used to treat diseases mediated with abnormality of FGFR-4 and /or FGF19, such as hepatocellular carcinoma and other forms of cancer.

PROCESS FOR PREPARING AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS

Disclosed herein is a process for preparing amide-substituted imidazo compounds. In particular, disclosed herein is the process for preparing certain amide-substituted imidazo compounds that are useful for inhibiting indoleamine 2, 3-dioxygenase and for treating diseases or disorders mediated thereby.

AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS AS SELECTIVE INHIBITORS OF INDOLEAMINE 2, 3-DIOXYGENASES

Disclosed herein are amide-substituted imidazo compounds and pharmaceutical compositions comprising at least one such novel benzoimidazoles, processes for the preparation thereof, and the method for using the same in therapy. In particular, disclosed herein are certain amide-substituted imidazo compounds that are useful for inhibiting indoleamine 2, 3-dioxygenase and for treating diseases or disorders mediated thereby.

Synthesis of several new 2-substituted benzimidazoles

A series of new 2-substituted ethyl-4-methyl-1 H-benzimidazole-6-carboxylates has been synthesised and one X-ray crystal structure determined that the synthetic method is reliable.

Calcitonin gene related peptide receptor antagonists

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.